- Ongoing, recruitingPhase II and Phase III (Integrated)
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
This study is testing a new medicine, brigimadlin, for people with advanced dedifferentiated liposarcoma. It compares brigimadlin to a standard medicine, doxorubicin, to see if it can slow down or stop the cancer from growing.
For: Advanced dedifferentiated liposarcomaNetherlands · Belgium · Czechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
Epirubicin for the Treatment of Sepsis & Septic Shock
This study is testing a medicine called Epirubicin for people in hospital with a serious infection called sepsis. Doctors want to see if it's safe and helps improve their condition. It's an early-stage study to learn more about the medicine's effects.
For: Patients with sepsis or septic shock · currently hospitalized at the Intensive Care Unit (ICU) or Intermediate Care (IMC) regardless where the sepsis was first diagnosed.Germany